Market Closed – Nasdaq
22:00:00 05.11.2024 % 5 Take % 1 Jan.
9,440 USD
+3,51 %
-6,26 %
+96,67 %
On November 5, 2024 at 11:14 p.m
Novavax said Tuesday that it has entered into an agreement with the U.K. health regulator to terminate and settle its COVID-19 vaccine supply contract. ]]]]>]]>
To the original article.
Legal Notice
Legal Notice
Contact us if you would like a correction
© Reuters – 2024
Novavax and UK end Covid-19 vaccine supply deal with $124 million repayment agreement 05:57 MT
Novavax and UK end vaccine supply agreement November 5th RE
Nigeria launches new Oxford R21 malaria vaccine October 17th. RE
NOVAVAX, INC. : Jefferies & Co. maintains a Buy rating at 10/16. ZM
New York stocks: There is no clear direction after the setback on October 16th. AW
US FDA pauses Novavax study of COVID-flu combination due to safety concerns 10/16. RE
Novavax’s COVID-19 Flu Vaccine Trial Put on Clinical Hold, Stocks Fall 10/16 MT
Novavax, Inc. Announces Update on Phase 3 Study of Covid-19 Influenza Combination and Stand-Alone Influenza Oct. 16. CI
NOVAVAX, INC. : B. Riley maintains a Buy rating at 10/10. ZM
Novavax’s updated COVID-19 vaccine receives EU approval 09.10. MT
Sector Update: Healthcare stocks steady before the bell on Wednesday October 9th. MT
Novavax receives EU marketing approval for updated vaccine Nuvaxovid COVID-19 09.10. MT
Novavax, Inc. Updated 2024-2025 Nuvaxovid? Covid-19 vaccine receives approval in the EU October 9th CI
Novavax launches updated COVID-19 vaccine in the US 09/13. MT
Novavax Announces Availability of Updated Covid-19 Vaccine with FDA Emergency Use Authorization September 13th CI
Novavax Announces that the Novavax COVID-19 Adjuvanted Vaccine Has Received Emergency Use Authorization from the US Food and Drug Administration 09/04. CI
Sector Update: Healthcare Stocks Rise Late Afternoon 8/30 MT
Novavax Receives FDA Emergency Use Authorization for Updated COVID-19 Vaccine Aug. 30 MT
More layoffs in the US and Canada as companies are uncertain about the economy 08/15. RE
More layoffs in the US and Canada as companies are unsettled by the economy 09.08. RE
Novavax shares fall after Q2 EPS, revenue misses estimates 8/8 MT
Novavax, Inc., Q2 2024 Earnings Call, Aug 08, 2024
08.08.
Novavax, Inc. Revises Full-Year 2024 Sales Guidance August 8th CI
Novavax Quarterly Revenue Misses Estimate Due to Weak COVID Vaccine Sales 8/8 RE
Novavax, Inc. Reports Earnings for the Second Quarter and Six Months Ended June 30, 2024 08/08. CI
Novavax, Inc. is a biotechnology company that researches, develops and markets vaccines to prevent serious infectious diseases. The company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented adjuvant Matrix-M to enhance the immune response. The Company has a commercial vaccine program for the prevention of COVID-19, which includes the prototype COVID-19 vaccine Nuvaxovid (NVX-CoV2373 or Prototype Vaccine) and the updated COVID-19 vaccine Nuvaxovid (NVX-CoV2601 or Updated Vaccine ) (collectively COVID-19 vaccine). The Company is advancing the development of other vaccine candidates, including the COVID19-Influenza Combination (CIC) vaccine candidate and other vaccine candidates. The COVID-19 vaccine and the other vaccine candidates contain the company’s proprietary adjuvant Matrix-M to enhance the immune response and stimulate higher levels of functional antibodies and trigger a cellular immune response. More company information Sell
Kaufen
Average Recommendation
STOCK UP
Last closing price
9,440 USD
Medium price target
17,83USD
Distance / Average price target
+88,91 %
Analyst estimates
Quarterly Sales – Deviation Rate
OUR EXPERTS ARE HERE FOR YOU
Monday – Friday 9:00 a.m. – 12:00 p.m. / 2:00 p.m. – 6:00 p.m
Imprint | Cookie settings | Copyright © 2024 . All rights reserved.
Stock quotes are provided by Factset, Morningstar and S&P Capital IQ
